Novo Nordisk launched Awiqli, introducing a once-weekly basal insulin injection for adults with diabetes. The treatment uses insulin icodec and reduces basal-insulin injection frequency from seven times weekly to once weekly. The launch represents a significant development in diabetes care, where daily injections can create practical and psychological barriers to treatment.
Weekly Insulin Could Change Diabetes Treatment Routines
Awiqli is supplied through prefilled FlexTouch pens containing 700 or 2,100 units. Novo Nordisk introduced the 700-unit pen at ₹2,611 and the 2,100-unit pen at ₹7,833. The company expects the treatment to address injection-related barriers that sometimes delay insulin initiation. However, fewer injections do not automatically guarantee improved glucose control or better adherence. The Weekly Insulin option requires careful prescribing, dose adjustment, and regular glucose monitoring.
The launch has commercial significance because India represents a major diabetes market with substantial unmet treatment needs. Novo Nordisk is competing against established daily basal-insulin brands, including Sanofi’s Lantus and lower-cost insulin glargine products. The Weekly Insulin launch could strengthen the company’s position through dosing convenience and a differentiated product offering. Its commercial performance will depend on affordability, physician recommendations, reimbursement arrangements, and sustained patient access.
Awiqli’s development was supported by the ONWARDS clinical programme, which evaluated insulin icodec against established basal insulins. The trials assessed blood-glucose control and safety across adults with type 2 diabetes. However, treatment recommendations and approved indications vary between countries. In India, the product has been launched for adults with type 1 and type 2 diabetes. Patients must not switch insulin schedules independently because weekly formulations require specific dosing instructions.
For patients, the Weekly Insulin treatment could make basal-insulin routines less burdensome, particularly for those struggling with daily injections. Yet insulin can cause hypoglycemia, including potentially severe episodes, and professional supervision remains essential. Clinicians must assess individual suitability, glucose patterns, and existing treatment before prescribing it. For Novo Nordisk, this launch represents an important commercial milestone in a market where convenience, affordability, and effective diabetes management increasingly influence treatment decisions.
